BioTek to be Awarded 2015 Governor’s Excellence in Worksite Wellness
News Feb 11, 2016
The award will be presented at the 2016 Worksite Wellness conference on March 30, 2016 in Burlington, VT. The conference highlights Vermont companies and their efforts to promote the health and wellness of employees. This year, Lilly Tarricone, Mark Boutin and Kathy Gendron at BioTek will be recognized for their leadership in BioTek’s BioFit wellness program.
BioTek’s continuing initiatives include a variety of activities, educational opportunities, generous health benefit premium incentives for participating employees, and other programs that appeal to their diverse workforce. The Company is also making strong strides in becoming a smoke-free campus by January 2017. Additionally, it sponsored a Fitbit® program, providing participating employees with free Fitbit devices to track activities and participate in virtual activity challenges as a group.
BioTek’s President and CEO, Briar Alpert, provided perspective, mentioning, “We collectively logged 200,000 miles on our Fitbits – this equates to over eight trips around the world, and is an amazing accomplishment that everyone can take pride in.”
“We’re pleased to note that our BioFit wellness program reaches beyond health and wellness benefits,” added Kathy Gendron, BioTek’s Vice President, Human Resources. “BioFit allows us to connect with each other, not just as colleagues, but as a family.”
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE